YS Biopharma Co., Ltd. (YS) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

YS Biopharma Co., Ltd. (YS) Healthcare & Pipeline Overview

YS Biopharma Co., Ltd. is a biotechnology firm specializing in the development of innovative vaccines and therapeutic biologics, leveraging its proprietary PIKA technology platform to address critical health challenges in infectious diseases and cancer, with a strong presence in both domestic and international markets.

What Is the Investment Thesis for YS?

YS Biopharma Co., Ltd. presents a unique investment thesis driven by its innovative PIKA technology platform and a diverse pipeline of vaccines and therapeutic biologics. The company is positioned to capitalize on the growing global demand for effective treatments in infectious diseases and cancer, with a market cap of $192M and a gross margin of 82.5%, indicating strong operational efficiency. Key growth catalysts include the increasing prevalence of infectious diseases and a heightened focus on vaccine development post-pandemic. However, potential risks include regulatory challenges and market competition, particularly from established players in the biotechnology sector. As the company continues to expand its product portfolio and geographic presence, it aims to enhance shareholder value through strategic partnerships and collaborations.

Based on FMP financials and quantitative analysis

YS Key Highlights

Market cap of $192M reflects the company's current valuation in the biotechnology sector.

• Gross margin of 82.5% indicates strong profitability potential relative to industry standards.
• P/E ratio of -0.33 suggests the company is currently operating at a loss, highlighting the need for revenue growth.
• Profit margin of -16.3% underscores the challenges in achieving profitability amid high R&D expenditures.
• Beta of 0.54 suggests lower volatility compared to the broader market, indicating a relatively stable investment.

Who Are YS's Competitors?

YS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are YS's Key Strengths?

Innovative PIKA technology platform enhances immune response.

• Strong gross margin of 82.5% indicating operational efficiency.
• Diverse product pipeline targeting high-demand therapeutic areas.
• Established international presence in key markets.

What Are YS's Weaknesses?

Negative profit margin of -16.3% reflecting current operational challenges.

• Dependence on regulatory approvals for product commercialization.
• Limited brand recognition compared to larger competitors.
• High R&D costs impacting short-term profitability.

What Could Drive YS Stock Higher?

Regulatory approvals for new vaccine candidates expected in 2026, which could enhance market presence.

• Development of innovative therapeutics leveraging PIKA technology platform to address infectious diseases.
• Strategic partnerships with healthcare providers and research institutions to expand product offerings.
• Expansion into emerging markets in Asia and Africa to capture growing demand for vaccines.
• Increased focus on R&D to innovate and enhance the product pipeline.

What Are the Key Risks for YS?

Financial-distress signal — its Altman Z-Score of -1.98 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory challenges that may delay product approvals and commercialization.
• Intense competition from established biotechnology firms could impact market share.
• Market volatility affecting funding for research and development initiatives.
• Dependence on successful product launches to achieve revenue growth.

What Are the Growth Opportunities for YS?

• Expansion into New Markets: YS Biopharma aims to expand its operations into emerging markets in Asia and Africa, where the demand for vaccines and therapeutics is growing rapidly. By leveraging its PIKA technology platform, YS can introduce its innovative products to these underserved regions, potentially capturing significant market share.
• Development of Novel Therapeutics: The company is focused on developing novel therapeutics targeting cancer and chronic infectious diseases. With the global cancer therapeutics market projected to reach $200 billion by 2026, YS's innovative approach to immunomodulation could provide a competitive edge. The ongoing research and development efforts in this area are expected to yield new products that can drive revenue growth in the coming years.
• Partnerships and Collaborations: YS Biopharma is actively seeking strategic partnerships with other biotechnology firms and research institutions to enhance its R&D capabilities. Collaborations can lead to shared resources, reduced costs, and accelerated product development timelines. By aligning with established players, YS can enhance its market position and drive innovation.
• Regulatory Approvals: The company is in the process of obtaining regulatory approvals for its vaccine candidates, which could significantly boost its market presence. Successful approvals can lead to increased sales and market penetration, particularly in regions with high demand for vaccines against infectious diseases. Timely regulatory success is crucial for YS's growth trajectory.
• Increased Focus on Infectious Disease Vaccines: The global focus on infectious disease prevention has intensified post-COVID-19, creating a favorable environment for vaccine development. YS Biopharma's existing pipeline, which includes vaccines for Rabies and Coronavirus, positions the company to capitalize on this trend. The increasing allocation of public health budgets towards vaccine initiatives can further support YS's growth.

What Are YS's Competitive Advantages?

• Proprietary PIKA technology platform provides a unique competitive advantage in immunomodulation.
• Strong focus on R&D enables continuous innovation and product development.
• Established presence in multiple international markets enhances brand recognition.
• Experienced leadership team with a track record in the biopharmaceutical industry.
• Robust pipeline of products targeting high-demand therapeutic areas such as infectious diseases.

What Does YS Do?

YS Biopharma Co., Ltd., founded in 2002 and headquartered in Beijing, China, is a pioneering biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics targeting infectious diseases and cancer. The company has established a robust proprietary PIKA immunomodulating technology platform, which enhances the immune response to various pathogens and cancer cells. YS Biopharma's product portfolio includes preventive and therapeutic biologics aimed at combating diseases such as Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. With operations spanning China, the United States, Singapore, the United Arab Emirates, and the Philippines, YS Biopharma is strategically positioned to tap into diverse markets and address global health needs. The company employs approximately 773 individuals, reflecting its commitment to innovation and research in the biopharmaceutical sector. Over the years, YS Biopharma has evolved from a domestic player to an international contender, leveraging its technological advancements and market insights to enhance its product offerings and expand its geographical reach.

What Products and Services Does YS Offer?

• Discover and develop vaccines for infectious diseases and cancer.
• Utilize proprietary PIKA immunomodulating technology to enhance immune responses.
• Manufacture therapeutic biologics targeting diseases such as Hepatitis B and Influenza.
• Commercialize products in multiple international markets including the US and Asia.
• Conduct research and development to innovate in the biopharmaceutical field.
• Collaborate with healthcare providers to address public health challenges.

How Does YS Make Money?

• Generate revenue through the sale of vaccines and therapeutic biologics.
• Leverage partnerships with governmental and private healthcare sectors for product distribution.
• Invest in R&D to develop innovative treatments that meet market needs.
• Utilize grants and funding for research initiatives to support product development.
• Expand into new markets to diversify revenue streams and reduce dependency on domestic sales.

What Industry Does YS Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in technology, increased investment in research and development, and a rising demand for innovative therapies. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with a CAGR of around 7.4%. YS Biopharma operates in a competitive landscape, facing rivals such as CRGX, FSTX, LENZ, PRDS, and SLRN, each vying for market share in the lucrative vaccine and therapeutic biologics sectors. The company's focus on infectious diseases and cancer positions it well within this expanding market, as healthcare providers and governments prioritize effective solutions for public health challenges.

Who Are YS's Key Customers?

• Healthcare providers and hospitals requiring vaccines and therapeutics.
• Government health agencies focused on public health initiatives.
• Research institutions seeking innovative biopharmaceutical solutions.
• Pharmaceutical companies interested in partnerships for product development.
• Patients in need of effective treatments for infectious diseases and cancer.

Wall Street analysts project YS Biopharma Co., Ltd. revenue of about $1.39B for fiscal 2026, with EPS near $1.01.

YS Biopharma Co., Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.98 places it in the distress zone, a signal of elevated financial risk.

Return on equity for YS Biopharma Co., Ltd. stands at -18.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.3%, showing how much profit it generates from its asset base. A current ratio of 1.02 indicates the company holds enough short-term assets to cover its near-term obligations.

YS Biopharma Co., Ltd. (YS) Valuation Context

Valued at $192M, YS is classified as a micro-cap stock. Relative to its peer group, YS's quantitative score of 54/100 is roughly in line with the peer average of 50/100.

Company Profile

YS Biopharma Co., Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Hui Shao. YS has traded publicly since 2021.

YS Financials

YS Latest News

YS Analyst Consensus

YS MoonshotScore

Common Questions About YS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources